Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer. by Zhang, Z. F. et al.
Britfsh Journal of Cancer (1995) 71, 888-893
©) 1995 Stockton Press All rights reserved 0007-0920/95 $12.00
Family history of cancer, body weight, and p53 nuclear overexpression in
Duke's C colorectal cancer
Z-F Zhang', Z-S Zeng2, AS Sarkis3, DS Klimstra4, E Charytonowicz4, D Pollack', J Vena5,
J Guillem2, JR Marshall5, C Cordon-Cardo4, AM Cohen2 and CB Begg'
'Department ofEpidemiology and Biostatistics, 2Colorectal Service, Department ofSurgery, 3Urology Service, Department of
Surgery, 'Department ofPathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 44, New York, NY 10021,
USA., 'Department ofSocial and Preventive Medicine, State University ofNew York at Buffalo, Buffalo, NY 14214, USA.
Summary To examine the hypothesis that colorectal carcinomas with and without TP53 mutations may be
characterised by aetiological heterogeneity, we analysed a group of 107 patients with primary Dukes' C
colorectal cancer seen at the Memorial Sloan-Kettering Cancer Center (MSKCC) from 1986 to 1990. We
assessed p53 overexpression using the monoclonal antibody PAb 1801, and identified 42 (39%) patients displaying
p53-positive phenotype, defined as >25% of positive cells. Patients with two or more first-degree relatives
with cancer had an odds ratio (OR) of 2.9 (95% CI 1.0-8.3) for p53 overexpression in comparison with those
without a family history of cancer (trend test, P = 0.11). A possible association between body weight and p53
overexpression was observed. The ORs were 1.9 for the second quartile, 1.9 for the third quartile and 3.4 for
the highest quartile in comparison with the lowest quartile (trend test, P = 0.06). No association between
occupational physical activity, smoking, drinking, parity and p53 overexpression was identified. The results
suggest that p53 overexpression may be related to genetic predisposition to colorectal cancer, and p53-positive
and p53-negative colorectal cancers may be controlled by different aetiological pathways.
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Colorectal cancer (CRC) is the second most common malig-
nancy of both sexes in developed countries (Parkin et al.,
1993). A total of 394 000 deaths are estimated to occur
annually for colorectal cancer, making it the third most
important cause of cancer mortality in the world (Pisani et
al., 1993). It is also a major public health problem in the
United States, with an estimated 149000 new cases diag-
nosed in 1994, including 107 000 of colon cancer and 42 000
of rectum cancer. The incidence ranks the third in males and
the second in females in the United States (American Cancer
Society, 1994). Epidemiological studies show that increased
risk of colorectal cancer may be associated with both genetic
and environmental factors (Potter et al., 1993). For the
genetic component of CRC, two major types of CRC predis-
position have been identified: familial adenomatous polyposis
(FAP), which is believed to account for 1% of CRC cases,
and hereditary non-polyposis colorectal cancer (HNPCC),
which is considered to explain about 4-15% of CRC cases
(Peltomaki et al., 1993). First-degree relatives of colorectal
patients have been reported to have an increased risk of
cancer. This type of familial clustering of cancer may be
caused by hereditary factors such as FAP or HNPCC or may
be related to environmental exposures since family members
may share similar environments. Environmental factors, such
as dietary fibre (Howe et al., 1992) and fat (Prentice et al.,
1990), have been found to play an important role in CRC
risk. In addition, occupational physical activity (Vena et al.,
1985), body weight (Lee and Paffenbarger Jr., 1992; Kreger
et al., 1992), reproductive factors (La Vecchia et al., 1991),
cholecystectomy (Zeng and Zhang, 1993), cigarette smoking
(Giovannucci et al., 1994a,b) and alcohol consumption
(Longnecker et al., 1990) have also been identified as possible
risk factors.
The TP53 gene represents a broad target for mutations.
Mutations at this locus are reported to be the most frequent
molecular abnormalities in human cancer. The TP53 gene is
associated with control of the cell cycle, DNA repair and
synthesis, cell differentiation, genomic plasticity and pro-
grammed cell death (Harris, 1993; Wyllie, 1993). Inactivation
of p53 can be caused by TP53 mutations, chromosomal
rearrangement and non-disjunction, gene conversion, imprin-
ting or mitotic recombination or by complexation with viral
oncoproteins such as the papilloma E6 or with the MDM2
gene product, p90 (Harris and Houstein, 1993). Mutated
TP53 loses its function as a tumour-suppressor gene and can
act as a dominant oncogene. Loss ofp53 function accelerates
the process of tumorigenesis and alters the response of cells
to agents that damage DNA (Levine et al., 1994). Mutant-
type p53 proteins have a prolonged half-life and are thus
more likely to be detected using immunohistochemical (IHC)
assays than the wild-type protein (Finlay et al., 1988).
Although increased expression of wild-type protein may
occur in response to DNA damage (Kastan et al., 1991),
identification of p53 nuclear accumulation by IHC has been
reported to correlate well with TP53 mutations, as deter-
mined by DNA sequencing analysis in a variety of tumours
(Marks et al., 1991; Cunningham et al., 1992; Vahakangas et
al., 1992; Dalbagni et al., 1993; Cordon-Cardo et al., 1994;
Jacquemier et al., 1994). TP53 mutational spectra can point
to particular leads in the aetiology and carcinogenesis of
cancer (Harris, 1993). Many studies have been conducted to
assess the association between p53 overexpression/mutations
and risk factors for a variety of cancers. Mutations or
overexpression of p53 have been associated with previous
exposure to cigarette smoking in lung (Kondo et al., 1992;
Miller et al., 1992; Suzuki et al., 1992), head and neck (Field
et al., 1991; Brachman et al., 1992), oesophageal (Hollstein et
al., 1991) and bladder cancers (Spruck et al., 1993; Zhang et
al., 1994a). It has also been related to the ageing in prostatic
adenocarcinoma (Zhang et al., 1994b) and associated with
exposures to ultraviolet light in squamous cell carcinoma
(Brash et al., 1991), and to aflatoxin exposure (Hollstein et
al., 1993) and hepatitis B virus (Hsu et al., 1993) in
hepatocellular carcinomas.
Recent reports reveal that TP53 mutations occur com-
monly (40-70%) in colorectal cancer (Darmon et al., 1994).
Mutations of the TP53 gene have been observed in the
progression of colonic polyps to colon cancer (Vogelstein et
al., 1988; Fearon and Vogelstein, 1990). We have previously
found that p53 nuclear overexpression correlates well with
poor survival in colorectal cancer (Zeng et al., 1994). Our
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November 1994hypothesis for the present study is that colorectal tumours
with positive or negative p53 nuclear staining may be charac-
terised by aetiological heterogeneity, which could reflect a
difference in the causal pathway, or could be indicative of a
difference in the magnitude of effect with the same mechan-
ism. To test the hypothesis, we employed case series study
design (Begg and Zhang, 1994) and examined the association
between p53 nuclear overexpression and risk factors such as
family history of cancer, body weight, occupational physical
activity, smoking, drinking and other factors in a group of
107 patients with primary Dukes' C colorectal cancer. This
study is one of a series of exploratory studies designed to
examine the prevalence of TP53 mutations and their associa-
tion with known and potential aetiological risk factors in a
series of solid tumours known to exhibit p53 overexpression.
Previous studies by our group have demonstrated that p53
overexpression is significantly associated with cigarette smok-
ing in bladder cancer (Zhang et al., 1994a) and ageing in
prostate cancer (Zhang et al., 1994b). To our knowledge,
there is no such study correlating risk factors with p53
transformed phenotypes in colorectal cancer.
Materials and methods
We reviewed the medical charts of consecutive patients with
colorectal cancer seen at Memorial Sloan-Kettering Cancer
Center from 1986 to 1990. Attention was restricted to
primary patients with Dukes' C colorectal cancer who had
potentially curative operations, regional lymph node metas-
tases and normal preoperative serum carcinoembryonic
antigen (CEA) levels (<5 ng ml-'). We studied a total of 107
(59 males, 48 females) patients with primary colorectal car-
cinoma. This series was previously studied for the prognostic
significance of p53 in colorectal carcinoma (Zeng et al.,
1994).
Information on family history of cancer, current occupa-
tion, smoking, drinking and other factors was abstracted
from the medical charts. Patients' body weights and heights
were measured by nurses on admission. Patients were inter-
viewed by surgeons or physicians using a standard admission
history form. The areas covered by the questions in this form
include 'tobacco consumption - extent and duration';
'alcohol consumption - extent and duration'; 'occupation';
and 'family history of cancer'. Among 107 patients, 104
(97%) had information on whether the patient had ever been
a smoker or a drinker. Ninety-two per cent (98/107) of
patients had information on family history of cancer. Current
occupational title was available for 104 (97%) patients, but
no specific occupational titles could be found for 11 patients
(10%) since they were recorded as 'retired'. Information on
diet was not available.
Tissue sections from these tumours and from ten normal
colonic mucosas were analysed immunohistochemically for
altered patterns of p53 expression, using a standard avidin-
biotin technique (Cordon-Cardo et al., 1987). The primary
antibody PAb 1801 was commercially obtained from Onco-
gene Science (Uniondale, NY, USA). This monoclonal anti-
body recognises a denaturation-resistant epitope located
between amino acids 32 and 79 which is present in both
wild-type and mutant human p53 protein (Banks et al.,
1986). For the immunohistochemical staining of p53, forma-
lin-fixed paraffin-embedded tissue was used; sections 4-6 gsm
thick were cut from blocks containing primary tumour. The
slides were incubated in an oven at 60°C for 1 h. After
deparaffinisation with xylene and rehydration through graded
alcohol, the sections were incubated in 1% hydrogen perox-
ide for 15 min to quench endogenous peroxidase activity.
Tissue sections were placed in 0.05% saponin solution
(Sigma, St Louis, MO, USA) for 30 min at room temp-
erature. Then the sections were rinsed with phosphate-
buffered saline (PBS).
For the reduction of non-specific background staining, a
10% solution of normal horse serum diluted with 2% bovine
serum albumin (BSA/PBS) was placed on the sections for
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30 min at room temperature. The serum was drained off and
sections were incubated with the mouse monoclonal antibody
PAb 1801 at the concentration of200 ng14l-I at 4°C. Sections
of a breast carcinoma known to contain mutant p53 protein
were used as a positive control. The specificity and accuracy
of immunoreaction was checked by negative control using
sections incubated with a class-matched, non-specific mouse
monoclonal antibody (Mlgsl-kp-1; PharMingen, San Diego,
CA, USA). Sections were rinsed in PBS and incubated with
secondary biotinylated horse anti-mouse antibodies (Vector
Laboratories, Burlingame, CA, USA) at 1:500 dilution, rins-
ed with PBS and then incubated with avidin-biotin-peroxi-
dase complexes (Vector Laboratories) at 1:25 dilution at
room temperature for 30 min. Following this, tissue sections
were rinsed in PBS and immunostaining was developed by
immersion in 0.06% 3,3'-diaminobenzidine tetrahydrochlor-
ide (DAB) solution dissolved in 0.5% Triton-X/PBS for
5 min. Sections were counterstained with modified Horris-
haematoxylin (Fisher) and 0.3% ammonia water and passed
through graded alcohols and xylene to dehydrate. Slides were
then observed by conventional light microscopy.
One investigator (DSK) reviewed the slides and scored the
IHC staining. In positive-staining cases, the percentage of
positively stained cells (<25%, 25-50%, 50-75%, >75%)
was estimated in order to determine the extent of p53 over-
expression. For statistical analysis, negative or patchy
(<25%) staining was considered as negative and heterogen-
eous or homogeneous (> = 25%) as positive. All specimens
were graded using a modification of the World Health
Organization classification, and staged according to the
TNM pathological staging system. Epidemiological risk fac-
tors were abstracted from the charts without knowledge of
the IHC results, and vice versa.
Based on the 42 cases with positive p53 and 65 cases with
negative p53 the minimum detectable odds ratio with 80%
power is approximately 3, so that only very strong associa-
tions would be statistically significant. Associations between
p53 nuclear overexpression and exposure to potential risk
factors, such as family history of cancer, body weight,
occupational physical activity, cigarette smoking and drink-
ing, were measured using the odds ratios (OR) and their 95%
confidence intervals (95% CI). The odds ratios represent the
ratio of the relative risk of the factors for p53-positive
tumours to the relative risks of the factors for p53-negative
tumours. Departures from a value of 1 may indicate aetio-
logical heterogeneity (Begg and Zhang, 1994). Trend tests
were performed to evaluate the dose-response relationship
(Breslow and Day, 1980). In evaluating family history of
cancer we first considered family history of any cancer in any
relatives; then, we evaluated family history of any cancer in
first-degree relatives; and, finally, we assessed the family his-
tory of a variety of individual cancer sites in the first-degree
relatives. Patients with a negative family history of cancer
were used as a reference group for analyses.
To assess the association between p53 overexpression and
occupational physical activity, we classified the occupational
titles reported by patients into one of five categories of
physical activity as rated by the Department of Labor in
their Estimates of Worker Trait Requirement (US Employ-
ment Service, 1956): (1) sedentary work, (2) light work, (3)
medium work, (4) heavy work and (5) very heavy work. Over
4000 jobs defined in the Dictionary of Occupational Titles
have been classified by the Department of Labor into one of
five degrees of physical activity (Vena et al., 1985). Patients
whose occupational titles were coded as 'retired', 'volunteer',
'self-employed', 'unemployed' or 'homemaker' were classified
into the median physical activity group (group 3).
Results
Characteristics ofpatients
Thirty-four per cent of the patients were aged less than 60
years, 35% were between the ages of 60 and 69 years andp53 and riskfactors in colorectal cancer
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Figure 1 Photomicrograph of colon tumour by PAb 1801
immunoreactivity: nuclei of tumour cells exhibited immunohis-
tochemical nuclear staining.
Table I p53 overexpression and demographic factors in colorectal
cancer
p53 Per cent
Variables No Yes positive OR and 95% CI
Age
<60 21 ;15 42 1.0
>60 44 27 38 0.9 0.4-1.9
Sex
Female 32 16 33 1.0
Male 33 26 44 1.6 0.7-3.5
Race
White 55 39 42 1.0
Non-white 7 3 30 0.6 0.1-2.5
Religion
Catholic 24 13 35 1.0
Protestant 12 10 46 1.5 0.5-4.5
Jewish 20 14 41 1.3 0.5-3.4
Other 5 3 38 1.1 0.2-5.4
Blood type
B 11 3 21 1.0
O 23 13 36 2.1 0.5-8.8
A 22 13 39 2.3 0.5-9.9
AB 3 3 50 3.7 0.5-28.4
31% were aged 70 or older; 55% were males and 88% were
white.
p53 nuclear overexpression in colorectal cancer
Ten morphologically normal colon specimens examined
showed absence of nuclear staining. Similarly, none of the
normal cells in all 107 colorectal tumours analysed showed
detectable p53 nuclear reactivity. However, 42 out of 107
(39%) tumour samples studied showed heterogeneous or
homogeneous nuclear staining for the anti-p53 PAb 1801
antibody. Positive staining is illustrated in Figure 1. The
distribution of demographic factors with p53 nuclear over-
expression is shown in Table I, and no associations are
apparent.
Family history ofcancer andp53 nuclear overexpression
Fifty-four patients (54/107; 50%) had one or more relatives
with cancer; 49 patients (49/107; 46%) had one or more
first-degree family members with cancer; and 21 patients
(21/107; 20%) had at least two first-degree relatives with
cancer. Nuclear overexpression of p53 was observed in 43%
ofpatients with a positive family history of cancer, compared
with 36% for patients without family history of cancer. This
resulted in an odds ratio of 1.3. Patients with two or more
Table H p53 overexpression and family history of cancer in
colorectal cancer cases
p53 Per cent
Variables No Yes positive OR and 95% CI
Family history of
cancer
No 28 16 36 1.0
Yes 31 23 43 1.3 0.6-2.9
Cancer history in first
degree relatives
No 28 16 36 1.0
Yes 28 21 43 1.3 0.6-3.0
1 member 20 8 29 0.7 0.3-1.9
>2 members 8 13 62 2.9 1.0-8.3
Trend test P = 0.11
Age <60
No 9 6 40 1.0
Yes 7 7 50 1.5 0.3-6.5
1 member 6 4 40 1.0 0.2-5.1
>2 members 1 3 75 4.5 0.4-54.2
Trend test P = 0.32
Age >60
No 19 10 34 1.0
Yes 21 14 40 1.3 0.5-3.5
1 member 14 4 22 0.5 0.1-2.1
>2 members 7 10 59 2.7 0.8-9.3
Trend test P = 0.16
Table III p53 overexpression and potential risk factors in colorectal
cancer cases
p53 Per cent
Variables No Yes positive OR and 95% CI
Weight (kg)
<=58 15 5 25 1.0
59-68 16 10 39 1.9 0.5-6.8
69-77 17 11 39 1.9 0.5-6.9
>=78 14 16 53 3.4 1.0-11.9
Trend test P = 0.06
Height (cm)
<=157 15 8 35 1.0
158-163 13 6 32 0.9 0.2-3.2
164-171 17 11 39 1.2 0.4-3.8
>= 172 17 17 50 1.9 0.6-5.6
Trend test P = 0.19
BMI (kgm2)
<=21.4 15 4 21 1.0
21.5-25.4 16 15 48 3.5 1.0-13.0
25.5-28.4 16 14 47 3.3 0.9-12.2
>=28.5 15 9 38 2.3 0.6-8.9
Trend test P = 0.42
Occupational physical
activity
Sedentary 15 11 42 1.0
Light 21 9 30 0.6 0.2-1.8
> =Medium 29 22 43 1.0 0.4-2.7
Trend test P = 0.77
Smoking
No 29 20 41 1.0
Yes 33 22 40 1.0 0.4-2.1
Drinking
No 21 16 43 1.0
Yes 41 26 39 0.8 0.4-1.9
Parity
None 8 6 43 1.0
1-2 26 18 41 0.9 0.3-3.1
3+ 27 17 39 0.8 0.2-2.8
Trend test P = 0.76
Marital status
Single 4 6 60 1.0
Married 47 30 39 0.4 0.1-1.6
Widowed/divorced 10 5 33 0.3 0.1-1.8p53andriskfactors in colorectal cancer
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first-degree relatives with cancer had an odds ratio of 2.9
(95% CI 1.0-8.3) for p53 overexpression in comparison with
those without family history of cancer (trend test, P=0.11)
(Table II). Patients who had a positive family history of
cancer were further examined according to the tumour site in
the first-degree relative. However, the data were too sparse to
reveal any obvious trends.
Weight, height andbody mass index (BMI) andpS3
overexpression
Increased body weight was associated with p53 overexpres-
sion. The odds ratio for p53 overexpression was 3.4 (1.0-
11.9) for those at the highest quartile, compared with individ-
uals at the lowest quartile (trend test, P = 0.06). No
significant relationship between height and p53 overexpres-
sion is suggested by the data (Table III). No evidence of
associations were found between p53 overexpression and
smoking, drinking, occupational physical activity and parity
(Table III).
Discussion
There are conflicting reports as to whether accumulation of
p53 protein as measured by immunohistochemical staining
always equates the actual frequency of TP53 genomic muta-
tions (Fisher et al., 1994). Rodrigues et al. (1990) found that
overexpression of p53 in colorectal cancer cell lines is
synonymous with mutation, but some mutations could not be
detected by IHC analysis. Cunningham et al. (1992) com-
pared molecular and IHC techniques in colorectal cancer,
and indicated that loss of heterozygosity of chromosome 17p
by tumour cells correlated well with positive labelling for
anti-p53 antibody. Our data (Dalbagni et al., 1993; Cordon-
Cardo et al., 1994) suggested that the accuracy of detecting
TP53 mutation by IHC was 90.3% in human bladder cancer.
Identification of p53 nuclear accumulation by IHC has also
been reported to correlate well with TP53 mutations, as
determined by DNA sequencing analysis in breast (Jacque-
mier et al., 1994), lung (Vahakangas et al., 1992), and
ovarian (Marks et al., 1991) cancers.
Our study ofcolorectal cancer is disadvantaged by the fact
that information on diet, the major risk factor, was un-
available because the study was retrospective, involving
abstraction of data from the medical record and analysis of
banked tissue specimens. The small sample size limits our
ability to detect associations. But at present biomarker
studies are difficult and expensive to conduct, and in context
our study has a larger sample size than most other published
molecular epidemiology studies (Field et al., 1991; Holstein et
al., 1991; Kondo et al., 1992; Suzuki et al., 1992; Spruck et
al., 1993). Information abstracted from medical charges may
be less reliable than from conventional interview studies.
However, since the information on risk factors was collected
by surgeons or physicians who interview patients using a
standard admission history form, the potential for mis-
classification may be similar to conventional interview or
questionnaire studies.
Family history of cancer is known to be associated with
increased risk of colorectal cancer (Neugut et al., 1993). In
this study, p53-positive tumours occur 2.9 times more fre-
quently in patients with two or more first-degree relatives
with cancer. After controlling for body weight, the odds ratio
was 3.0 (1.0-9.2). Our findings indicate that p53 overexpres-
sion may be related to genetic predisposition in colorectal
cancer. It is possible that germline mutations may be present
in the TP53 gene in some high-risk families, and that this is
responsible for the association observed in our study.
Increased body weight has also been identified as a possi-
ble risk factor (Kreger et al., 1992; Lee and Paffenbarger Jr.,
1992). We found that the odds ratio of p53 overexpression
was 3.4 for individuals at the highest quartile of body weight
compared with those at the lowest quartile. The odds ratio
was 3.1 (0.9-11.4) when adjusting for first-degree family
members with cancer. The mechanism for the relationship
between body weight and the risk of colorectal cancer is
obscure. Increased body weight may be related to increased
fat or caloric intake, decreased physical activity and meta-
bolic and hormonal changes owing to increased body fat
(Neugut et al., 1993). Body weight correlates to dietary fat
intake. In animals, high intake of dietary fat stimulates the
secretion of bile and fatty acids. Increased concentration of
bile and fatty acids in the colon may damage the surface
epithelium of the colon, which in turn stimulates the replica-
tion of colonic epithelial cells (Lee and Paffenbarger Jr.,
1992). Since a high proportion of transition-type point muta-
tions of the TP53 gene have been found in human colon
cancers, the association between increased body weight and
p53 overexpression may, in part, be due to those endogenous
determinants involved in carcinogenesis (Harris, 1993;
Renault et al., 1993).
We assessed the relationship between occupational physical
activity and p53 overexpression and found no association.
Since the occupational information obtained from the
medical charts was the last occupation or the occupation at
admission, our data may not accurately reflect lifetime occu-
pational activity. We observed no apparent association
between p53 overexpression and cigarette smoking in colorec-
tal cancer in contrast to our earlier study of bladder cancer
(Zhang et al., 1994a).
We have shown that the odds ratio relating risk factors to
the presence ofa biological marker is an appropriate measure
for characterising the degree of aetiological heterogeneity
between the disease groupings defined by the biomarker
(Begg and Zhang, 1994). In this study, we found that in
patients with two or more first-degree members with cancer
and those with high body weights had higher prevalence of
p53 overexpression, which indicates that p53 overexpression
may be related to genetic predisposition to colorectal cancer,
and p53-positive and -negative colorectal cancers may be
controlled by different aetiological pathways.
Acknowledgements
This publication was made possible in part by Grant No. ROI ES-
06718 (Dr Zuo-Feng Zhang) from the National Institute of Environ-
mental Health Science and Grant No. ROI CA47538 (Dr Carlos
Cordon-Cardo) from the National Cancer Institute, National Insti-
tute of Health, Department of Health and Human Services, and by
Career Development Award 93-20 (Dr Jose Guillem) from the
American Cancer Society.
References
AMERICAN CANCER SOCIETY. (1994). Cancer Facts & Figures -
1994. American Cancer Society: Atlanta.
BANKS L, MATLASHEWSKI G AND CRAWFORD L. (1986). Isolation
ofhuman-p53-specific monoclonal antibodies and their use in the
studies of human p53 expression. Eur. J. Biochem., 159,
529-534.
BEGG CB AND ZHANG ZF. (1994). Statistical analysis of molecular
epidemiology studies employing case-series. Cancer Epidemiol.
Biomarkers Prev., 3, 173-175.
BRACHMAN DG, GRAVES D, VOKE E, BECKETT M, HARAD D,
MONTAG A AND 4 OTHERS. (1992). Occurrence of p53 gene
deletions and human papilloma virus infection in human head
and neck cancer. Cancer Research, 52(17), 4832-4836.
BRASH DE, RUDOLPH JA, SIMON JA AND 5 OTHERS. (1991). A role
for sunlight in skin cancer: UV-induced p53 mutations in
squamous cell carcinoma. Proc. Natl Acad. Sci. USA, 88,
10124-10128.p53 and riskfactors in cdoroecl cancer
Z-F Zhang etal
892
BRESLOW NE AND DAY NE. (1980). Statistical Methods in Cancer
Research, Vol. 1, The Analysis of Case-Control Studies IARC
Scientific Publications No. 32. Vol. 1, pp. 122-159. IARC:
Lyon.
CORDON-CARDO C, FINSTAD CL, BANDER NH, OLD UJ AND
MELAMED M. (1987). Immunoanatomic distribution of cysto-
structural and tissue-associated antigens in the human urinary
tract. Am. J. Pathol., 126, 269-284.
CORDON-CARDO C, DALBAGNI G, SAEZ GT, OLIVA MR, ZHANG
ZF, ROSAI J, REUTER VE AND PELLICER A. (1994). p53 muta-
tions in human bladder cancer: genotypic versus phenotypic pat-
terns. Int. J. Cancer, 56, 347-353.
CUNNINGHAM J, LUST JA, SCHAID DJ, BREN GD, CARPENTER HA,
RIZZA E, KOVACH JS AND THIBODEAU SN. (1992). Expression
of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res.,
52, 1974-1980.
DALBAGNI G, PRESTI J, REUTER VE, ZHANG ZF, SARKIS A, FAIR
WR AND CORDON-CARDO C. (1993). Molecular genetic altera-
tions of chromosome 17 and p53 nuclear overexpression in
human bladder cancer. Diagnostic Mol. Pathol., 2(1), 4-13.
DARMON E, CLEARY KR AND WARGOVICH MJ. (1994). Immuno-
histochemical analysis of p53 overexpression in human colonic
tumors. Cancer Detection Prev., 18(3), 187-195.
FEARON ER AND VOGELSTEIN B. (1990). A genetic model for
colorectal tumorigenesis. Cell, 61, 759-767.
FIELD JK, SPANDIDOS DA, MALLIRI A, GOSNEY JR, YIAGNISIS M
AND STELL PM. (1991). Elevated P53 expression correlates with a
history ofheavy smoking in squamous cell carcinoma of the head
and neck. Br. J. Cancer, 64, 573-577.
FINLAY CA, HINDS PW, TAN TH, ELIYAHU D, OREN M AND
LEVINE AJ. (1988). Activating mutations for transformation by
p53 produce a gene product that forms an hsc70-p53 complex
with an altered half-life. Mol. Cell. Biol., 8, 531-539.
FISHER CJ, GILLETT CE, VOJTESEK B, BARNES DM AND MILLIS
RR. (1994). Problems with p53 immunohistochemical staining:
the effect of fixation and variation in the methods of evaluation.
Br. J. Cancer, 69, 26-31.
GIOVANNUCCI E, GOLDITZ GA, STAMPFER MJ, HUNTER D, ROS-
NER BA, WILLETT WC AND SPEIZER FE. (1994a). A prospective
study of cigarette smoking and risk of colorectal adenoma and
colorectal cancer in U.S. women. J. Natl Cancer Inst., 8(3),
192-199.
GIOVANNUCCI E, RIMM EB, STAMPFER MJ, GOLDITZ GA, ASCHE-
RIO A, KEARNEY J AND WILLETT WC. (1994b). A prospective
study of cigarette smoking and risk of colorectal adenoma and
colorectal cancer in US men. J. Natl Cancer Inst., 86(3),
183-191.
HARRIS CC. (1993). p53: at the crossroads of molecular car-
cinogenesis and risk assessment. Science, 262, 1980-1981.
HARRIS CC AND HOLLSTEIN MC. (1993). Clinical implications of
the p53 tumor-suppressor gene. N. Engl. J. Med., 329,
1318-1327.
HOLLSTEIN MC, PERI L, MANDARD AM, WELSH JA, MONTESANO
R, METCALF RA, BAK M AND HARRIS CC. (1991). Genetic
analysis of human esophageal tumors from two high incidence
geographic areas: frequent p53 base stubstitutions and absence of
ras mutations. Cancer Res., 51, 4102-4106.
HOLLSTEIN MC, WILD CP, BLEICHER F, CHUTIMATAEWIN S, HAR-
RIS CC, SRIVATANAKUL P AND MONTESANO R. (1993). p53
mutations and alfatoxin B1 exposure in hepatocellular carcinoma
patients from Thailand. Int. J. Cancer, 53, 51-55.
HOWE GR, BENITO E, CASTELLETO R, CORNEE J, ESTEVE J, GAL-
LAGHER RP, ISCOVICH JM, DENG-AO J, KAAKS R, KUNE GA,
KUNE S, L'ABBE KA, LEE HP, LEE M, MILLER AB, PETERS RK,
POTTER JD, RIBOLI E, SLATTERY ML, TRICHOPOULOS D,
TUYNS A, TZONOU A, WHITTEMORE AS, WU-WILLIAMS AH
AND SHU Z. (1992). Dietary intake of fiber and decreased risk of
cancers of the colon and rectum: evidence from the combined
analysis of 13 case control studies. J. Natl Cancer Inst., 84,
1887-1896.
HSU IC, TOKIWA T, BENNETT W, METCALF RA, WELSH JA, SUN T
AND HARRIS CC. (1993). p53 gene mutation and integrated
hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis, 14, 987-992.
JACQUEMIER J, MOLES JP, PENAULT-LLORCA F, ADELAIDE J,
TORRENTE M, VIENS P, BIRNBAUM D AND THEILLET C.
(1994). p53 immunohistochemical analysis in breast cancer with
four monoclonal antibodies: comparison of staining and
PCR-SSCP results. Br. J1. Cancer, 69, 846-852.
KASTAN MB, ONYKEWERE 0, SIDRANSKY D, VOGELSTEIN B AND
CRAIG RW. (1991). Participation of p53 protein in the cellular
response to DNA damage. Cancer Res., 51, 6304-6311.
KONDO K, UMEMOTO A, AKIMOTO S, UYAMA T, HAYASHI K,
OHNISHI Y. AND MONDEN Y. (1992). Mutations in the P53
tumour suppressor gene in primary lung cancer in Japan.
Biochem. Biophys. Res. Commun., 183, 1139-1146.
KREGER BE, ANDERSON KM, SCHATZKIN A AND SPLANKSKY
GA. (1992). Serum cholesterol level, body mass index, and the
risk of colon cancer: the Framingham study. Cancer, 70,
1038-1043.
LAVECCHIA C AND FRANCESCHI S. (1991). Reproductive factors
and colorectal cancer. Cancer Causes Control, 2, 193-200.
LEE I-M AND PAFFENBARGER JR RS. (1992). Quetelet's index and
risk of colon cancer in college alumni. J. Natl Cancer Inst., 84,
1326-1331.
LEVINE AJ, CHANG PA, DITTMER AS, WU M AND WELSH D.
(1994). The 1993 Walter Hubert Lecture: the role of the p53
tumour-suppressor gene in tumorigenesis. Br. J. Cancer, 69,
409-416.
LONGNECKER MP, ORZA MJ, ADAMS ME, VIOQUE J AND CHAL-
MERS TC. (1990). A meta-analysis of alcoholic beverage con-
sumption in relation to risk of colorectal cancer. Cancer Causes
Control, 1, 59-68.
MARKS JR, DAVIDOFF AM, KERNS BJ, HUMPHREY PA, PENCE JC,
DODGE RK, CLARKE-PEARSON DL AND IGLEHART JD. (1991).
Overexpression and mutation of p53 in epithelial ovarian cancer.
Cancer Res., 51, 2979-2984.
MILLER CW, SIMON K, ASLO A, KOK K, YOKOTA J, BUYS CH,
TERADA M AND KOEFFLER HP. (1992). p53 mutations in
human lung tumors. Cancer Res., 52, 1695-1698.
NEUGUT AI, JACOBSON JS AND DEVIVO I. (1993). Epidemiology of
colorectal adenomatous polyps. Cancer Epidemiol. Biomarkers
Prev., 2, 159-176.
PARKIN DM, PISANI P AND FERLAY J. (1993). Estimate of the
world incidence ofeighteen major cancers in 1985. Int. J. Cancer,
54, 594-606.
PELTOMAKI P, AALTONEN LA, SISTONEN P, PYLKKANEN L,
MECKLIN J-P, JARVINEN H, GREEN JS, JASS JR, WEBER JL,
LEACH FS, PETERSEN GM, HAMILTON SR, DE LA CHAPELLE A
AND VOGELSTEIN B. (1993). Genetic mapping of a locus predis-
posing to human colorectal cancer. Science, 260, 810-812.
PISANI P, PARKIN DM AND FERLAY J. (1993). Estimates of the
world mortality from eighteen major cancers in 1985. Implication
and projections of future burden. Int. J. Cancer, 55, 891-903.
POTTER JD, SLATTERY ML, BOSTICK RM AND GAPSTUR SM.
(1993). Colon cancer: a review of the epidemiology. Epidemiol.
Rev., 15 (2), 499-545.
PRENTICE RL AND SHEPPARD L. (1990). Dietary fat and cancer:
consistency of the epidemiological data, and disease prevention
that may follow from a practical reduction in fat consumption.
Cancer Causes Control, 1, 81-97.
RENAULT B, VAN DEN BROEK M, FODDE R, WIJNEN J, PELLEGATA
NS, AMADORI D, KHAN PM AND RANZANI GN. (1993). Base
transitions are the most frequent genetic changes at P53 in gastric
cancer. Cancer Res., 53, 2614-2617.
RODRIGUES NR, ROWAN A, SMITH ME, KERR IB, BODMER WF,
GANNON JV AND LANE DP. (1990). p53 mutations in colorectal
cancer. Proc. Nati Acad. Sci. USA, 87, 7555-7559.
SPRUCK III CH, RIDEOUT III WM, OLUMI AF, OHNESEIT PF, YANG
AS, TSAI YY, NICHOLS PW, HORN T, HERMANN GG, STEVEN K,
ROSS RK, YU MC AND JONES PA. (1993). Distinct pattern ofp53
mutations in bladder cancer: relationship to tobacco usage.
Cancer Res., 53, 1162-1166.
SUZUKI H, TAKAHASHI T, KUROISHI T, SUYAMA M, ARIYOSHI Y
AND UEDA R. (1992). p53 mutations in non-small cell lung
cancer in Japan: association between mutations and smoking.
Cancer Res., 52, 734-736.
US EMPLOYMENT SERVICE DEPARTMENT OF LABOR, BUREAU
OF EMPLOYMENT SECURITY. (1956). Estimates of Worker Trait
Requirements for 4,000 jobs as Defined in the Dictionary of
Occupational Titles (an alphabetical index). USGPO: Washing-
ton, DC.
VAHAKANGAS KH, SAMET JM, METCALF RA, WELSH JA, BEN-
NETT WP, LANE DP AND HARRIS CC. (1992). Mutations of p53
and ras genes in radon-associated lung cancer from uranium
miners. Lancet, 339, 576-580.
VENA JE, GRAHAM 5, ZIELENZNY M, SWANSON MK, BARNES RE
AND NOLAN J. (1985). Lifetime occupational exercise and colon
cancer. Am. J. Epidemiol., 122(3), 357-365.
VOGELSTEIN B, FEARON ER, HAMILTON SR, KERN SE AND 6
OTHERS. (1988). Genetic alterations during colorectal tumor
development. N. Engl. J. Med., 319, 525.
WYLLIE AH. (1993). Apoptosis (The 1992 Frank Rose Memorial
Lecture). Br. J. Cancer, 67, 205-208.p53 and riskfactors In cdoral cancer
Z-F Zhang etal 0
893
ZENG ZS AND ZHANG ZF. (1993). Cholecystectomy and colorectal
cancer in China. Surgical Oncol., 2, 311-319.
ZENG ZS, SARKIS AS, ZHANG ZF, KLIMSTRA DS, CHARYTONO-
WICZ E, GUILLEM JG, CORDON-CARDO C AND COHEN AM.
(1994). p53 nuclear overexpression: an independent predictor of
survival in lymph node positive colorectal cancer patients. J. Clin.
Oncol., 12 (10), 2043-2050.
ZHANG ZF, SARKIS AS, CORDON-CARDO C, DALBAGNI G, MELA-
MED J, APRIKIAN A, POLLACK D, SHEINFELD J, HERR HW,
FAIR WR, REUTER VE AND BEGG C. (1994a). Tobacco smoking,
occupation, and p53 nuclear overexpression in early stage bladder
cancer. Cancer Epidemiol. Biomarkers Prev., 3, 19-24.
ZHANG ZF, APRIKIAN A, SARKIS AS, ZENG ZS, POLLACK D,
CORDON-CARDO C, FAIR WR AND BEGG CB. (1994b). Factors
associated with p53 accumulation in prostatic adenocarcinoma.
Int. J. Oncol., 4, 897-901.